Post Content
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the stocks Jim Cramer discussed alongside the tech market divide. Toward the end of the lightning round, a caller sought Cramer’s thoughts on the company, and here’s what he had to say in response:
I think Regeneron, I think Leonard Schleifer’s doing an unbelievable job. I think the stock’s breaking out here, I really do. I mean, I looked at it for the Charitable Trust, that and Amgen, we bought another stock, but those are the two I really like.
A stock market data. Photo by AlphaTradeZone on Pexels
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for eye conditions, immune disorders, cancer, cardiovascular issues, infections, and rare diseases. A caller inquired about the stock during the March 2 episode, and Cramer replied:
Oh man, you know what? I should have pulled the trigger on Regeneron when I sat down with them at the JPMorgan conference. I realized that the Charitable Trust should have owned it. It would’ve a much better, really much better drug stock than the others that we have, with the exception of Eli Lilly.
While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.